SCHEMBL668603

SCHEMBL668603

CC(=O)S[C@@H](C)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6896886 1.00
SCHEMBL15669276 1.00
SCHEMBL15974698 0.79 FFAR3 (0.35)
SCHEMBL16077445 0.79
SCHEMBL31323093 0.79 TP53 (0.42)
SCHEMBL7309246 0.78 TP53 (0.36)
SCHEMBL7263270 0.78 TP53 (0.36)
SCHEMBL13873968 0.78
SCHEMBL9313930 0.74
SCHEMBL19522869 0.74 TP53 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3114138-B1 IMPROVED MUTEINS OF CLOTTING FACTOR VIII PFIZER (US) 2021-11-17 EP disclosed
US-20200392205-A1 MUTEINS OF CLOTTING FACTOR Vlll PFIZER (US) 2020-12-17 US disclosed
US-10570189-B2 Muteins of clotting factor VIII PFIZER INC. (US) 2020-02-25 US disclosed
US-20150306234-A1 MUTEINS OF CLOTTING FACTOR Vlll PFIZER INC. 2015-10-29 US disclosed
US-8618266-B2 Hasylated polypeptides FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2013-12-31 US disclosed
EP-1681303-B1 HASylated polypeptides, especially HASylated erythropoietin FRESENIUS KABI DE GMBH (DE) 2013-09-04 EP disclosed
US-8475765-B2 Hydroxyalkyl starch derivatives FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2013-07-02 US disclosed
EP-2143736-B1 Hydroxyalkyl starch derivatives FRESENIUS KABI DE GMBH (DE) 2012-11-07 EP disclosed
US-20120046240-A9 Method of Producing Hydroxyalkyl Starch Derivatives FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2012-02-23 US disclosed
EP-2316850-A2 HASylated polypeptides, especially HASylated erythropoietin Fresenius Kabi Deutschland GmbH (DE) 2011-05-04 EP disclosed
EP-0728144-B1 PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEINASES DARWIN DISCOVERY LTD (GB) 2000-01-19 EP disclosed
CN-1046525-C Compounds containing a fused bicyclic ring and processes therefor BRISTOL MYERS SQUIBB CO (US) 1999-11-17 CN disclosed
US-5853623-A Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases CHIROSCIENCE LIMITED (GB) 1998-12-29 US disclosed
US-5756832-A REACTING AN ALDHYDE WITH AN ORTHOFORMATE IN THE PRESENCE OF AN ACID CATALYST AND AN ALCOHOL BRISTOL-MYERS SQUIBB CO. (US) 1998-05-26 US disclosed
US-5672599-A DUAL ACTION ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS; TREATMENT OF CARDIOVASCULAR DISORDERS BRISTOL-MYERS SQUIBB CO. (US) 1997-09-30 US disclosed
US-5670699-A Process for preparing amino acid esters useful as intermediates for compounds containing a fused bicyclic ring BRISTOL-MYERS SQUIBB CO. (US) 1997-09-23 US disclosed
US-5627278-A MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION BRISTOL-MYERS SQUIBB CO. (US) 1997-05-06 US disclosed
US-5616775-A ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE BRISTOL-MYERS SQUIBB CO. (US) 1997-04-01 US disclosed
US-5508272-A SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1996-04-16 US disclosed
EP-0629627-A2 Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1994-12-21 EP disclosed